CDxDiagnostics_Logo.png
NOTICE TO DISREGARD -- CDx Diagnostics
May 04, 2021 11:13 ET | CDx Diagnostics
SUFFERN, N.Y., May 04, 2021 (GLOBE NEWSWIRE) -- We are advised by CDx Diagnostics that journalists and other readers should disregard the news release, “CDx Diagnostics Contracts with Wellmark Blue...
CDxDiagnostics_Logo.png
WATS3D Receives Medically Necessary Designation from Blue Cross Blue Shield of Kansas City
March 09, 2021 11:00 ET | CDx Diagnostics
SUFFERN, N.Y., March 09, 2021 (GLOBE NEWSWIRE) -- WATS3D, a diagnostic platform used by physicians to detect Barrett’s esophagus (BE), pre-cancer and cancerous cells in the esophagus, has received a...
CDxDiagnostics_Logo.png
WATS3D Now Considered Medically Necessary by BlueCross BlueShield of South Carolina
January 26, 2021 14:00 ET | CDx Diagnostics
SUFFERN, N.Y., Jan. 26, 2021 (GLOBE NEWSWIRE) -- WATS3D, an AI-powered diagnostic platform developed by CDx Diagnostics to identify precancerous and cancerous cells in the esophagus, is now...
CDxDiagnostics_Logo.png
CDx Diagnostics Awarded Federal Supply Schedule Contract
December 15, 2020 11:30 ET | CDx Diagnostics
Veterans now have access to WATS3D life-saving technology in the VA and community settings SUFFERN, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- CDx Diagnostics has been awarded GSA Contract...
CDxDiagnostics_Logo.png
Study Confirms WATS3D as Cost-Effective Adjunct to Seattle Protocol
August 25, 2020 13:00 ET | CDx Diagnostics
The addition of WATS3D to the screening process for BE resulted in approximately 3 fewer cancers and 3 fewer cancer deaths per 1,000 people screened SUFFERN, N.Y., Aug. 25, 2020 (GLOBE NEWSWIRE) --...
CDxDiagnostics_Logo.png
CDx Diagnostics Announces Contract with Hawaii Medical Services Association
August 11, 2020 14:30 ET | CDx Diagnostics
WATS3D diagnostic platform for screening and surveillance ofBarrett’s esophagus now available to 800,000 members SUFFERN, N.Y., Aug. 11, 2020 (GLOBE NEWSWIRE) -- CDx Diagnostics, Inc. is now...
CDxDiagnostics_Logo.png
SAGES TAVAC Analysis Indicates WATS3D is a Safe and Effective Diagnostic Technique for Barrett’s Esophagus
June 16, 2020 13:00 ET | CDx Diagnostics
SUFFERN, N.Y., June 16, 2020 (GLOBE NEWSWIRE) -- WATS3D, an AI-powered diagnostic platform used to identify precancerous cells in the esophagus, has been deemed as a safe and effective adjunctive to...
CDx_Logo_Blue-tight (1).png
CDx Diagnostics Announces Contract with Blue Cross Blue Shield of Massachusetts for WATS3D Biopsy
April 02, 2020 08:00 ET | CDx Diagnostics
- Newly issued coverage statement on diagnostic platform for screening and surveillance of Barrett’s esophagus - SUFFERN, N.Y., April 02, 2020 (GLOBE NEWSWIRE) -- Effective Jan. 21, 2020 – CDx...
American Society for Gastrointestinal Endoscopy Includes WATS3D in Its New Practice Guideline for the Screening and Surveillance of Barrett’s Esophagus
September 04, 2019 09:00 ET | CDx Diagnostics
SUFFERN, N.Y., Sept. 04, 2019 (GLOBE NEWSWIRE) -- CDx Diagnostics, developer of the WATS3D diagnostic platform for the screening and surveillance of Barrett’s esophagus (BE), a known precursor to...
CDx_Logo_Blue-tight (1).png
New Data Presented at DDW 2019 Demonstrate That WATS3D Provides Clinical Benefit in Detecting Residual/Recurrent Intestinal Metaplasia in Post-Barrett’s Esophagus Ablation Patients
May 18, 2019 12:30 ET | CDx Diagnostics
- Study shows that the addition of WATS3D increased the detection of residual/recurrent intestinal metaplasia by 79% and associated dysplasia by 224% - SUFFERN, N.Y., May 18, 2019 (GLOBE NEWSWIRE)...